trial

Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)

NCTId NCT03510325
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 762 (actual)
Sponsored by Shanghai Mental Health Center
Primary completion 2023-09-27
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
762 (actual)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Single
Start
2019-02-12
Primary completion
2023-09-27
Eligibility
ALL · 16 Years · 45 Years

Interventions & indications

Drugs
OlanzapineRisperidoneAmisulprideAripiprazolePerphenazineClozapine

Sponsors

Shanghai Mental Health CenterLead Sponsor

Sites

7 total
Beijing, ChinaWuhan, ChinaNanjing, ChinaDalian, ChinaShanghai, ChinaKunming, ChinaHangzhou, China

Linked catalysts

1
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatm — primary completion2023-09-27

Facts & assertions

4 sourced
Enrollment
762
Phase
PHASE3
Primary Completion Date
2023-09-27
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Risperidone
drug
Amisulpride
drug
Aripiprazole
drug
Perphenazine
drug
Clozapine
drug
lead_sponsor
Shanghai Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication